Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models
- 24 March 2013
- journal article
- research article
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 108 (3) , 1-10
Abstract
Mitochondrial aldehyde dehydrogenase-2 (ALDH-2) is involved in preconditioning pathways, but its role in remote ischaemic preconditioning (rIPC) is unknown. We investigated its role in animal and human models of rIPC. (i) In a rabbit model of myocardial infarction, rIPC alone reduced infarct size [69 ± 5.8 % (n = 11) to 40 ± 6.5 % (n = 12), P = 0.019]. However, rIPC protection was lost after pre-treatment with the ALDH-2 inhibitor cyanamide (62 ± 7.6 % controls, n = 10, versus 61 ± 6.9 % rIPC after cyanamide, n = 10, P > 0.05). (ii) In a forearm plethysmography model of endothelial ischaemia–reperfusion injury, 24 individuals of Asian ethnic origin underwent combined rIPC and ischaemia–reperfusion (IR). 11 had wild-type (WT) enzyme and 13 carried the Glu504Lys (ALDH2*2) polymorphism (rendering ALDH-2 functionally inactive). In WT individuals, rIPC protected against impairment of response to acetylcholine (P = 0.9), but rIPC failed to protect carriers of Glu504Lys polymorphism (P = 0.004). (iii) In a second model of endothelial IR injury, 12 individuals participated in a double-blind placebo-controlled crossover study, receiving the ALDH-2 inhibitor disulfiram 600 mg od or placebo for 48 h prior to assessment of flow-mediated dilation (FMD) before and after combined rIPC and IR. With placebo, rIPC was effective with no difference in FMD before and after IR (6.18 ± 1.03 % and 4.76 ± 0.93 % P = 0.1), but disulfiram inhibited rIPC with a reduction in FMD after IR (7.87 ± 1.27 % and 3.05 ± 0.53 %, P = 0.001). This study demonstrates that ALDH-2 is involved in the rIPC pathway in three distinct rabbit and human models. This has potential implications for future clinical studies of remote conditioning.Keywords
This publication has 36 references indexed in Scilit:
- Effect of mitochondrial aldehyde dehydrogenase-2 genotype on cardioprotection in patients with congenital heart diseaseEuropean Heart Journal, 2012
- ALDH2 Activator Inhibits Increased Myocardial Infarction Injury by Nitroglycerin ToleranceScience Translational Medicine, 2011
- Cardioprotection by Remote Ischemic Preconditioning Exhibits a Signaling Pattern Different From Local Ischemic PreconditioningShock, 2011
- Preservation of peripheral vasodilation as a surrogate of cardioprotection? The mechanistic role of ATP-dependent potassium channels and the mitochondrial permeability transition poreEuropean Heart Journal, 2011
- Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehydeEuropean Heart Journal, 2010
- Activation of aldehyde dehydrogenase 2 (ALDH2) confers cardioprotection in protein kinase C epsilon (PKCɛ) knockout miceJournal of Molecular and Cellular Cardiology, 2010
- Aldehyde Dehydrogenase 2 in Cardiac Protection: A New Therapeutic Target?Trends in Cardiovascular Medicine, 2009
- Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) StudyCirculation, 2009
- Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the HeartScience, 2008
- ACCF/AHA/SCAI 2007 Update of the Clinical Competence Statement on Cardiac Interventional ProceduresCirculation, 2007